While systematic cross-tissue validation remains an important future research direction, current evidence supports the reliability and clinical utility of peripheral blood–derived episignatures, even though this is not the primary tissue affected in NOTCH1-related CHD. The gene discussed is NOTCH1; the disease is coronary artery disorder.